Pearson v. Shalala Case Brief
Complete case briefs with LSD+
Every LSD.Law brief pairs a full IRAC analysis with opinion summaries at three levels of depth, written by a team of Harvard Law and MIT graduates - a quick synopsis when you are pressed for time, the complete reasoning when you need to go deep.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: The court reversed the FDA’s denial of dietary supplement health claims, finding the agency violated the First Amendment by not considering disclaimers and the APA by not defining its approval standard.
Legal Significance: This case reinforces that the First Amendment prefers disclaimers over suppression for potentially misleading commercial speech and requires agencies to articulate clear standards for their decisions under the APA.
Pearson v. Shalala Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Appellants, marketers of dietary supplements, sought FDA authorization for four health claims on their product labels, such as “Consumption of antioxidant vitamins may reduce the risk of certain kinds of cancers.” The FDA, pursuant to the Nutrition Labeling and Education Act (NLEA) and its regulations (21 C.F.R. § 101.14(c)), authorizes such claims only if it finds “significant scientific agreement” among experts that the claim is supported by available evidence. The FDA rejected all four of appellants’ proposed claims, concluding the evidence was inconclusive and thus did not meet this standard. The agency, however, had not provided a clear definition of “significant scientific agreement.” Furthermore, the FDA refused to consider appellants’ suggestion to authorize the claims if accompanied by disclaimers clarifying the inconclusive nature of the supporting evidence (e.g., “The FDA has determined that the evidence supporting this claim is inconclusive.”). Appellants challenged the FDA’s decisions in district court, arguing violations of their First Amendment rights and the Administrative Procedure Act (APA). The district court rejected their challenges.
Court Holding & Legal Precedent
Issue: Did the FDA’s refusal to authorize appellants’ health claims for dietary supplements, based on an undefined “significant scientific agreement” standard and without considering the use of disclaimers as a less restrictive alternative to a complete ban, violate the First Amendment’s protection of commercial speech and the Administrative Procedure Act?
Yes. The FDA’s refusal to authorize the health claims without adequately considering Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
IRAC Legal Analysis
About IRAC analysis
IRAC (Issue, Rule, Analysis, Conclusion) is the structure professors expect in exam answers. Each LSD.Law brief states the issue, the governing rule with citations, the court's application of that rule, and the conclusion - the same reasoning pattern you will use on exams and in practice.
Legal Issue
Did the FDA’s refusal to authorize appellants’ health claims for dietary supplements, based on an undefined “significant scientific agreement” standard and without considering the use of disclaimers as a less restrictive alternative to a complete ban, violate the First Amendment’s protection of commercial speech and the Administrative Procedure Act?
Conclusion
This decision significantly impacts commercial speech doctrine by reinforcing the government's burden Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
Legal Rule
1. Under the First Amendment, restrictions on potentially misleading commercial speech are Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum d
Legal Analysis
The court first analyzed the First Amendment commercial speech claim (Part II.A). Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id es
Flash-to-Full Case Opinions
Flash Summary
- The FDA’s total ban on dietary supplement health claims not meeting